In patients with chronic epiphora due to partial, complete, or functional nasolacrimal duct obstruction, is lacrimal gland botulinum toxin injection more effective at reducing subjective symptoms as compared to placebo?

Trial Profile

In patients with chronic epiphora due to partial, complete, or functional nasolacrimal duct obstruction, is lacrimal gland botulinum toxin injection more effective at reducing subjective symptoms as compared to placebo?

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Euphoria
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top